Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKN1 | Q16512 | 1/20 | 0.77 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.77 |
| ▸ | DHODH | Q02127 | 13/20 | 0.73 |
| ▸ | PARP1 | P09874 | 7/20 | 0.70 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.60 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.59 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7322715 | 0.97 | PKN1 (0.81) | PKN1PKN2DHODHPARP1PLA2G2A | |
| SCHEMBL2815222 | 0.90 | PKN1 (0.77) | PKN1PKN2DHODHPARP1PLA2G2A | |
| SCHEMBL29087633 | 0.90 | PKN1 (0.77) | PKN1PKN2DHODHPARP1PLA2G2A | |
| SCHEMBL22453146 | 0.88 | PKN1 (0.75) | PKN1PKN2DHODHPARP1PLA2G2A | |
| SCHEMBL2811097 | 0.88 | PARP1 (0.77) | PKN1PKN2DHODHPARP1PLA2G2A | |
| Acetic Acid SCHEMBL7318987 | 0.88 | PARP1 (0.72) | PKN1PKN2DHODHPARP1PLA2G2A | |
| SCHEMBL1170810 | 0.87 | PKN1 (0.77) | PKN1PKN2DHODHPARP1PLA2G2A | |
| SCHEMBL25220279 | 0.87 | PKN1 (1.00) | PKN1PKN2DHODHPARP1PLA2G2A | |
| SCHEMBL30440938 | 0.87 | PKN1 (1.00) | PKN1PKN2DHODHPARP1PLA2G2A | |
| SCHEMBL7313257 | 0.85 | PKN1 (0.74) | PKN1PKN2DHODHPARP1PLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2414328-B1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | MERCK SERONO SA (CH) | 2021-05-26 | — | — | EP | disclosed |
| EP-2414328-B1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | MERCK SERONO SA (CH) | 2021-05-26 | — | — | EP | disclosed |
| US-9006454-B2 | Dihydroorotate dehydrogenase inhibitors | MERCK SERONO S.A. (CH) | 2015-04-14 | — | — | US | disclosed |
| US-9006454-B2 | Dihydroorotate dehydrogenase inhibitors | MERCK SERONO S.A. (CH) | 2015-04-14 | — | — | US | disclosed |
| US-9006454-B2 | Dihydroorotate dehydrogenase inhibitors | MERCK SERONO S.A. (CH) | 2015-04-14 | — | — | US | disclosed |
| EP-2414328-A2 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | Merck Serono S.A. (CH) | 2012-02-08 | — | — | EP | disclosed |
| US-20120028959-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | MERCK SERONO S.A. (CH) | 2012-02-02 | — | — | US | disclosed |
| US-20120028959-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | MERCK SERONO S.A. (CH) | 2012-02-02 | — | — | US | disclosed |
| US-20120028959-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | MERCK SERONO S.A. (CH) | 2012-02-02 | — | — | US | disclosed |
| WO-2010115736-A2 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | MERCK SERONO S.A. (CH) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010115736-A2 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | MERCK SERONO S.A. (CH) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028959-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | DHODH, FH, DPYD | PKN1 3639/4885PKN2 3767/4885DHODH 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.